Fig. 5

Inhibition of PGD₂ and metabolite-induced cell activation with DP₂ inhibitor fevipiprant. Cells were incubated with ascending concentrations of fevipiprant and stimulated with EC₇₀ concentrations of PGD₂, DK-PGD₂, ∆¹²-PGD₂, 15-deoxy-∆^12,14-PGD₂, PGJ₂, 9a,11b-PGF₂, ∆¹²-PGJ₂ and 15-deoxy-∆^12,14-PGJ₂, respectively. A, B Inhibition of eosinophil shape change, n = 3–5. Top constraints equal 100. C, D Inhibition of ILC2 migration, n = 4. Top constraints equal 100. E, F Inhibition of ILC2 IL-5 secretion, n = 4. Bottom constraints equal zero. (G,H) Inhibition of ILC2 IL-13 secretion, n = 4. Bottom constraints equal zero. Values are given as mean ± SEM